News
IT | 2010-06-15
TxCell achève avec succès le développement préclinique de TX-RAD pour traiter les arthrites inflammatoires. Ces résultats favorables permettront à TxCell de démarrer prochainement un nouvel essai clinique de Phase I/IIa
Valbonne, France, le 15 Juin 2010 – TxCell SA, une entreprise française de biotechnologies qui développe des thérapies cellulaires autologues utilisant des lymphocytes T régulateurs de type 1 (Tr1) pour traiter les maladies chroniques inflammatoires et auto-immunes, annonce aujourd’hui le succès du développement préclinique de son produit TX-RAD pour le traitement des arthrites inflammatoires.
Suite à l’obtention de données précliniques solides, TxCell prépare à présent une étude clinique avec TX-RAD pour le traitement des patients atteints de polyarthrite rhumatoïde modérée à sévère. La demande d’autorisation d’essai clinique sera soumise au cours du troisième trimestre de l’année 2010.
« La pharmacologie préclinique, incluant les données de pharmacodynamique, pharmacocinétique et de toxicologie, a montré des preuves concrètes de la tolérance et de l’efficacité de TX-RAD, un nouveau produit de thérapie cellulaire pour traiter les arthrites inflammatoires, » déclare Arnaud Foussat, Directeur Scientifique de TxCell.
Suite à l’obtention de données précliniques solides, TxCell prépare à présent une étude clinique avec TX-RAD pour le traitement des patients atteints de polyarthrite rhumatoïde modérée à sévère. La demande d’autorisation d’essai clinique sera soumise au cours du troisième trimestre de l’année 2010.
« La pharmacologie préclinique, incluant les données de pharmacodynamique, pharmacocinétique et de toxicologie, a montré des preuves concrètes de la tolérance et de l’efficacité de TX-RAD, un nouveau produit de thérapie cellulaire pour traiter les arthrites inflammatoires, » déclare Arnaud Foussat, Directeur Scientifique de TxCell.
Le développement futur de TX-RAD bénéficiera d’un procédé de production robuste, établi selon les BPF (Bonnes Pratiques de Fabrication) durant la phase de recherche préclinique.
« Ce programme préclinique réussi est une nouvelle étape importante dans le développement de notre société et apporte une validation supplémentaire pour notre plateforme technologique, » ajoute Frédéric Hammel, Président du Directoire de TxCell. « Nous sommes à présent prêts à soumettre la demande d’autorisation de notre prochain essai clinique, essai pour lequel nous devrions réaliser la première injection d’ici la fin de l’année. »
La polyarthrite rhumatoïde est une maladie chronique, souvent invalidante qui présente un véritable besoin médical non satisfait. Les traitements existants n’apportent pas encore de réponse complète.
TX-RAD est une préparation autologue de cellules T régulatrices de type 1 (cellules Tr1) formulée pour une injection intraveineuse. Les cellules Tr1 utilisées dans TX-RAD sont isolées à partir d’un échantillon de sang complet du patient, activées par l’antigène spécifique, identifiées et multipliées ex vivo avant d’être réinjectées au patient. Les cellules Tr1 injectées migrent vers les sites inflammatoires et sont activées localement par l’antigène spécifique, le collagène de type II, qui est une protéine majoritairement présente dans les articulations.
TX-RAD représente potentiellement une nouvelle opportunité de traitement pour les patients atteints d’une polyarthrite rhumatoïde modérée à sévère et qui ne répondent pas aux traitements conventionnels existants.
La preuve solide de la tolérance et de l’efficacité de ce nouveau produit pour traiter la polyarthrite rhumatoïde sera confirmée au travers de l’essai clinique programmé. La documentation de pré-soumission a déjà été réalisée et la demande d’autorisation d’essai clinique finale sera soumise d’ici la fin de l’été.
« Cet essai de Phase I/IIa est conçu comme une étude en escalade de doses pour une première injection chez l’homme, » déclare Miguel Forte, Directeur Médical de TxCell. « Les données de tolérance et d’efficacité obtenues dans les études précliniques, ainsi que le signal positif détecté dans l’essai de Phase I/IIa pour la maladie de Crohn avec des cellules Tr1, nous fournissent des informations pertinentes pour sélectionner les doses et les schémas adéquats pour la conception de cet essai exploratoire, ouvert, de Phase I/IIa dans la polyarthrite rhumatoïde. »
A propos de l’essai clinique de Phase I/IIa dans la polyarthrite rhumatoïde
L’étude de Phase I/IIa d’escalade de doses, de 12 semaines, multicentrique, ouverte, est conçue pour évaluer la sécurité et l’efficacité de la thérapie TX-RAD chez des patients atteints d’une polyarthrite rhumatoïde modérée à sévère. Cette étude sera conduite en France et fait partie du projet CellArthrix.
A propos du projet CellArthrix
Le projet CellArthrix est le résultat d’une collaboration entre TxCell (Valbonne), l’unité Inserm U844 du Professeur Jorgensen et le Centre Hospitalier Régional Universitaire (Montpellier) et TcLand (Nantes).
Le projet CellArthrix a été labélisé par le pôle de compétitivité Eurobiomed et est partiellement financé par le Fonds Unique Interministériel (FUI), les Régions Provence Alpes Côte d’Azur et Pays de la Loire, et par le Conseil Général des Alpes-Maritimes.
A propos de TxCell
TxCell SA, spin-off de l'Inserm (Institut National de la Santé et de la Recherche Médicale), a été créée en 2001. La société développe une approche immuno-modulatrice innovante, utilisant des cellules vivantes pour régénérer l’équilibre du système immunitaire dans les maladies chroniques inflammatoires et auto-immunes. Les produits de TxCell se présentent sous la forme de suspensions cellulaires injectables de clones autologues de lymphocytes T régulateurs de type 1 (Tr1) spécifiques d’un antigène.
TxCell mène actuellement son premier essai clinique d’une thérapie à base de lymphocytes T régulateurs (Tr1) pour le traitement de la maladie de Crohn. Les résultats finaux de cette Phase I/IIa sont attendus pour fin 2010. La société est basée dans le parc technologique de Sophia Antipolis, près de Nice dans le sud de la France.
Life Science | 2010-06-08
Zealand Pharma Announces An Extension of The Lixisenatide Global Licensing Agreement with sanofi-aventis for Type-2 Diabetes
Copenhagen, 08 June 2010 : Zealand Pharma A/S, the biopharmaceutical company dedicated to the discovery and development of innovative peptide-based drugs, is pleased to announce that the global licensing agreement with sanofi-aventis has been amended to provide for the development and commercialization of Lixisenatide (AVE0010/ZP10) in combination with Lantus, Sanofi-aventis’ recombinant human insulin analog.
Lixisenatide is a Zealand-invented GLP-1 (glucagon-like-peptide-1) receptor agonist for the treatment of Type-2 Diabetes, and uses Zealand’s proprietary SIP™ (structure inducing probe) peptide modification technology. Lantus® is sanofi-aventis’ number one brand with 2009 sales of more than €3 Billion. In April 2010, sanofi-aventis reported positive Phase III results from the first of nine clinical studies within the Lixisenatide GetGoal Phase III program. Filing of Lixisenatide is expected to take place in H2 2011 in Europe & H2 2012 in the US.
The Phase III clinical program for the Lantus® + Lixisenatide combination product is expected to commence in 2010. Zealand knows of no similar Type-2 Diabetes product that is as advanced in clinical testing.
The companies restructured the financial terms of the agreement to provide Zealand with payments for the achievement of development, regulatory, and sales milestones for the Lantus® + Lixisenatide combination product. Zealand expects to receive a part of such payments in 2010 as the combination product advances into Phase III. Royalties (low double digits) to Zealand for Lixisenatide and the Lantus® + Lixisenatide combination product as well as other non-disclosed provisions of the agreement have been further amended providing value for both companies.
Commenting on today’s announcement David Solomon, Chief Executive Officer and President of Zealand Pharma, said: “We are delighted that sanofi-aventis, one of the world’s leading diabetes care companies, has reinforced its long and successful relationship with Zealand Pharma. This agreement not only strengthens Zealand’s financial position, allowing us to progress our other pipeline programs, but also provides significant excitement globally around a superior treatment for patients suffering with Type-2 Diabetes. We look forward to the ongoing clinical development of Lixisenatide and of the Lantus® + Lixisenatide combination product. Our focus at Zealand continues to be to build shareholder value through the development of leading peptide-based drugs.”
For further information please contact:
Zealand Pharma A/S
David Solomon, President and Chief Executive Officer
Zealand Pharma A/S, Smedeland 36, DK-2600 Copenhagen, Denmark
Tel: +45 4328 1200, Fax: +45 4328 1212, E-mail: info@zp.dk
M:Communications
Mary-Jane Elliott / Emma Thompson
Tel: +44(0) 20 7920 2300, E-mail: Zealandpharma@mcomgroup.com
Notes for Editors
About Diabetes and Type-2 Diabetes(Source: WHO)
· More than 220 Million people worldwide have diabetes
· In 2005, an estimated 1.1 Million people died from diabetes
· Almost 80% of diabetes deaths occur in low- and middle-income countries
· Almost half of diabetes deaths occur in people under the age of 70 years; 55% of diabetes deaths are in women
· WHO projects that diabetes deaths will double between 2005 and 2030
· Healthy diet, regular physical activity, maintaining a normal body weight and avoiding tobacco use can prevent or delay the onset of diabetes
Type-2 Diabetes results from the body’s ineffective use of insulin. Type-2 Diabetes comprises 90% of people with diabetes around the world, and is largely the result of excess body weight and physical inactivity. Symptoms may be similar to those of Type 1 diabetes, but are often less marked. As a result, the disease may be diagnosed several years after onset, once complications have already arisen. Until recently, this type of diabetes was seen only in adults but it is now also occurring in children.
About Lantus®
Lantus®, a recombinant human insulin analog, is sanofi-aventis’ number one brand with 2009 sales over €3 Billion. Lantus® is indicated for once-daily subcutaneous administration in the treatment of adult patients with Type-2 Diabetes who require basal (long-acting) insulin for the control of hyperglycemia and for adult and pediatric patients (6 years and older) with type 1 diabetes mellitus. Lantus® is described by sanofi-aventis as providing a steady 24-hour release of insulin for blood sugar control with one shot a day at the same time each day, with no pronounced peak. For more information, please visit www.lantus.com.
About sanofi-aventis
Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY). For more information please visit www.sanofi-aventis.com.
About Zealand Pharma A/S
Zealand Pharma A/S is a biopharmaceutical company dedicated to the discovery and development of innovative peptide-based drugs. Zealand Pharma is a leader in peptide drug development, a growing market with significant drug development activities including treatment of diabetes, obesity, gastro-intestinal, metabolic and cardiovascular diseases. All of Zealand Pharma’s products target diseases and indications with significant unmet clinical need and commercial potential.
Since 1999, Zealand Pharma’s scientists have built a pipeline that includes five compounds in clinical development, four of which have been out licensed, three of these to major pharmaceutical companies (sanofi-aventis, Wyeth (now part of Pfizer) and Helsinn Healthcare). All of Zealand Pharma’s compounds emerge from Zealand Pharma’s own drug discovery. Currently in the diabetes portfolio, Zealand Pharma has the following drugs in development:
· Lixisenatide (AVE0010/ZP10), a pharmaceutical agent for the treatment of Type-2 Diabetes, has been out-licensed to sanofi-aventis, the world’s third largest pharmaceutical corporation with a strong Diabetes franchise. Phase III clinical trials for Lixisenatide in monotherapy are being conducted by sanofi-aventis. The Phase III clinical program for the Lantus® + Lixisenatide combination product is expected to start in 2010.
· ZP2929 is a novel, potent, long-acting dual Glucagon-GLP-1 agonist aiming to provide a novel treatment option for people with Type-2 Diabetes and obesity. ZP2929 entered preclinical development in 2009 and has already demonstrated improved glycaemic control as well as significant and sustained body weight loss in pre-clinical pharmacology models.
In addition, Zealand Pharma has a rich and broad peptide portfolio of pre-clinical projects targeting a variety of disease areas, including Type-1 Diabetes and Type-2 Diabetes.
Zealand Pharma A/S is based in Copenhagen. The Company’s investors include, Sunstone Capital, Allianz Private Equity, CDC Innovation, LD Pensions, Dansk Erhvervsinvestering and LSP.
For more information please visit Zealand Pharma’s web site: www.zealandpharma.com.
Life Science | 2010-06-02
Cytheris Closes €12 Million ($15 Million) Series D Financing
Proceeds Will Further Advance Studies of Interleukin-7 in HIV, HBV, HCV and Oncology
Paris (France) – June 2, 2010 – Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that it has completed a €12 million ($15 million) Series D financing. New investor, CDC Entreprises (France), acting for the Strategic Investment Fund (FSI), participated in the round along with existing investors Bioam Gestion (France), Caisse de dépôt et Placement du Québec (Canada), CDC Innovation (France), Crédit Agricole Private Equity (France), and Forbion Capital Partners (The Netherlands). Jones Day Paris served as Company counsel.
In conjunction with the CDC Entreprises investment, Marie-Laure Garrigues, Director of Investments at CDC Entreprises, will join the Cytheris board of directors as an observer.
"Cytheris has an outstanding team working on the new frontier of immunotherapy, one of the most exciting areas of current medical development," said Ms. Garrigues. "We appreciate the opportunity to support the company's efforts in the critical areas of unmet medical need represented by HIV, hepatitis and oncology."
Proceeds from this financing will be used to accelerate development in the Company’s IL-7 (CYT107) clinical programs in HIV, HBV, HCV and oncology.
“We are delighted to welcome CDC Entreprises as an investor and Marie-Laure Garrigues as a board observer and are especially grateful for the continued support from our existing investors,” said Michel Morre, DVM, President and CEO of Cytheris. “This financing provides us with the resources to aggressively advance CYT107 through clinical trials, particularly in the HIV and hepatitis markets.”
“After demonstrating the quality of IL-7 induced immune reconstitution in most patients treated in our HIV studies, we are now focusing these investigations on showing that repeated cycles of IL-7 can induce long term or definitive immune restoration,” added Dr. Morre, “while our HCV and HBV studies are aimed at documenting the production of specific antiviral T cells, potentially offering long term protection.”
About Interleukin-7 (CYT107)
Recombinant human interleukin-7 (CYT107) is a critical immune-modulator for immune Tcell recovery and enhancement. As a growth factor and cytokine physiologically produced by marrow or thymic stromal cells and other epithelia, IL-7 has a critical and, at some steps, a non-redundant stimulating effect on T lymphocyte development, notably on thymopoïesis and, downstream from the thymus, on homeostatic expansion of peripheral T-cells.
Clinical trials conducted on more than 140 patients in Europe, North America and Taiwan have demonstrated a consistent safety and tolerability profile as well as the potential of IL-7 to expand and protect CD4+ and CD8+ T-cells in various pathologic conditions.
Currently, Cytheris is conducting multiple international investigations of IL-7 in HIV, HBV, HCV, idiopathic CD4 lymphocytopenia (sponsored by NIAID/NIH) and cancer, the latter including an NCI/NIH-sponsored study of IL-7 in combination with dendritic cell vaccines in a pilot study of tumor vaccination in children, and a study designed to restore CD4+ and CD8+ counts following T-cell depletion due to bone marrow or peripheral blood stem cell transplant (being conducted at the Memorial Sloan-Kettering Cancer Center in New York
City).
About Cytheris -- www.cytheris.com
Cytheris SA is a privately held clinical-stage biopharmaceutical company focused on research and development of new therapies for immune modulation. These drugs aim at reconstituting and enhancing the immune system of patients suffering from cancer, chronic viral or bacterial infections such as HCV, HBV and HIV, or lympho-depleting treatments such as chemotherapy, radiotherapy, bone marrow transplantation (BMT) and hematopoietic cell transplantation (HCT). The company operates from its headquarters and laboratories in Issy-les-Moulineaux, a suburb of Paris, and its U.S. subsidiary in Rockville, Maryland.IT | 2010-05-20
Novaled demonstrates long lifetime and high efficiency white top emitting OLEDs
Dresden, Germany, 20th May 2010
Novaled, a leading company in OLEDs for display and lighting applications, demonstrates white top-emitting devices with a lifetime exceeding 50,000 h and a power efficiency of 30 lm/W at an initial luminance of 1,000 cd/m2.
The white top emitting OLED structure offers the realisation of OLED lighting products made on metal substrates. Metal substrates bring advantages such as good heat dissipation, mechanical stability, bended designs and open the roadmap towards low cost roll-to-roll production.
Novaled has developed a high performance white top emitting OLED using the Novaled PIN OLED® technology with its proprietary doping and host materials in association with a blue flourescent emitting material from SFC Korea. In addition the device has an ITO-free top contact and corporates a Novaled-specific light extraction material layer to enhance the efficiency. At the same time this outcoupling material reduces the color shift over a wide viewing angle so that it can hardly be detected by the naked eye.
The device achieves a lifetime above 50,000 h (t50) at an initial brightness of 1,000 cd/m2. This long lifetime translates into continuous device operation for more than 5 years. By using Novaled’s proprietary doping technology, the device reaches a high power efficiency of 30 lm/W measured in an integrating sphere. Broad emission spectrum and good CIE color coordinates (0.46/0.42) were achieved in the devices, which is close to illuminant A and inside the US Department of Energy (DOE) quadrangles.
“With this achievement Novaled demonstrates once again the robustness and potential of its PIN technology”, says Gildas Sorin, Novaled CEO. “Configurations like top or bottom, inverted or non-inverted organic structures with various emitting materials and metal electrodes bring the proper high performance for each specific market request in the display and lighting domain.”
about OLEDs
OLEDs (organic light-emitting diode) are semiconductors that are made of thin organic material layers that measure just a few nanometers in thickness. They emit light in a diffuse way to form an area light source. This disruptive technology represents an entirely new approach for architects, designers, system integrators, planners and luminarie makers when working with light. OLED lighting has a dual nature, which means it can function both as a lamp and a luminarie. OLEDs herald the future of a vast array of completely new lighting applications and by combining color with shape, OLEDs will create a new way of decorating and personalizing surroundings with light. Furthermore, organic LEDs will make a significant contribution to sustainability due to their energy efficiency, environmentally friendly materials and reduced packaging requirements.
about Novaled
Novaled AG is a world leader in the OLED field and specializes in high efficiency long lifetime OLED structures and is an expert in organic electronics. The company is known for its Novaled PIN OLED® technology, its proprietary OLED materials and the customized OLED products and services. Novaled has developed long term partnerships with major OLED producers throughout the world. Based on more than 400 patents granted or pending, Novaled has a strong IP position in the field of OLED technology, and was named No. 1 in a list of ‘up and coming’ world market leaders by the German newspapers Handelsblatt and Wirtschaftswoche. Its main investors include eCAPITAL, Crédit Agricole Private Equity, TechnoStart, TechFund and CDC Innovation. For further details please visit www.novaled.com.
IT | 2010-04-29
Novaled demonstrates reliable OLEDs on metal substrates
Dresden, Germany, 29th April 2010
Novaled, a leading company in OLEDs for display and lighting applications, demonstrated it’s know how and expertise on efficient and long lifetime OLEDs on metal at the Light and Building Frankfurt.
Novaleds PIN OLEDs on metal substrates combine the attractive appearance and superior physical properties of the metal substrates with the unique features of Novaled OLEDs such as long lifetime of up to 20.000 hrs. Metal substrates like steel or aluminium have excellent barrier properties, flexibility and robustness for handling. OLEDs on metal can be used in applications where magnetic clipping of the OLEDs is intended or where soldering, drilling and similar assembly steps are required. Furthermore, metal will also allow for bended or bendable OLED solutions. As this substrate material has very good heat conducting properties, OLEDs on metal are advantageous in application where heat dissipation is critical. In addition, metal substrate opens the roadmap towards low cost roll-to-roll mass production of OLEDs.
Novaled has a profound know how on how to build OLEDs on metal. Together with Arcelor Mittal Novaled has been developing OLED structures for steel substrates since 2006. In the German project Rollex Novaled contributed since 2007 to develop OLEDs on flexible aluminium substrates.
“Besides demonstrating excellent results with OLEDs on glass Novaled has developed a unique know how on OLEDs on metal”, says Gildas Sorin, CEO Novaled AG. “With OLEDs on metal Novaled is extending the range of lighting applications and solutions to specific market needs.”
The OLEDs manufactured by Novaled for luminaires and light sculptures shown at Light + Building Frankfurt are processed directly on steel plates of 0.7mm thickness. The metal substrate requires specific top emitting OLED structures. Novaled has developed a dedicated ITO free OLED architecture reaching performances similar to standard bottom emission structures. In addition Novaled is developing thin film encapsulation which will enable bended OLEDs.
about OLEDs
OLEDs (organic light-emitting diode) are semiconductors that are made of thin organic material layers that measure just a few nanometers in thickness. They emit light in a diffuse way to form an area light source. This disruptive technology represents an entirely new approach for architects, designers, system integrators, planners and luminaire makers when working with light. OLED lighting has a dual nature, which means it can function both as a lamp and a luminaire. OLEDs herald the future of a vast array of completely new lighting applications and by combining color with shape, OLEDs will create a new way of decorating and personalizing surroundings with light. Furthermore, organic LEDs will make a significant contribution to sustainability due to their energy efficiency, environmentally friendly materials and reduced packaging requirements.
about Novaled
Novaled AG is a world leader in the OLED field and specializes in high efficiency long lifetime OLED structures and is an expert in organic electronics. The company is known for its Novaled PIN OLED® technology, its proprietary OLED materials and the customized OLED products and services. Novaled has developed long term partnerships with major OLED producers throughout the world. Based on more than 400 patents granted or pending, Novaled has a strong IP position in the field of OLED technology, and was named No. 1 in a list of ‘up and coming’ world market leaders by the German newspapers Handelsblatt and Wirtschaftswoche. Its main investors include eCAPITAL, Crédit Agricole Private Equity, TechnoStart, TechFund and CDC Innovation. For further details please visit www.novaled.com.
IT | 2010-04-26
ASK and FORMASET to create a Joint Venture in Brazil Newly founded ASK-FORMASET will address the South American market
São Paulo, Brazil, Cards 2010 South America, April 26, 2010: Today ASK and FORMASET are pleased to announce that they have entered into an agreement for creation of a Joint Venture based in Brazil. ASK a world leader in contactless technology, and FORMASET, a key player in the printing of security documents in the telecommunications and lotteries, bring their experience and expertise together to become a major actor in contactless technology and its applications in Brazil. This joint venture will address the transportation and eID market mainly in Brazil.
“With their secure plant and ongoing ISO certification, FORMASET is highly aware of quality and security matters. FORMASET has been created in 1990 and the company’s knowledge of the market is an asset we can rely on. Transit is the main driver of Brazil growing smart card market and ASK could not disregard this huge potential, says Amand Cochet, VP Marketing and Business Line at ASK and member of the board of ASK-FORMASET. ”
FORMASET clients include such key accounts as VIVO, CLARO or Banco do Brasil and the team comprises highly experienced executives who come from the ticketing, smart card and transportation industry.
“ASK is a prominent actor of contactless technology and our newly founded Joint Venture is a great opportunity for FORMASET to offer new services to current and future clients, says Rossano Bertollo, General Manager and member of the board of ASK-FORMASET. The 2014 World Cup and 2016 Summer Olympic Games will no doubt boost the country and innovative transport and multiplication ticketing will be welcome, he adds.”
ASK-FORMASET facilities and manufacturing center locations will be disclosed in a few weeks.
About ASK
ASK, with over 160 million contactless products in circulation in more than 50 countries, is a worldwide leading provider of a full range of contactless products including smart cards, smart tickets, smart adhesive labels, readers, inlays for electronic passports or contactless smart cards and eDocuments. ASK is ISO9001 certified and holds a portfolio of 55 patents to date. ASK is a France-headquartered company with worldwide customers, and subsidiaries in Singapore, China, India, Mexico and the US.
About FORMASET
FORMASET, founded in 1990 started as a printing company for invoices and forms. Today, FORMASET offers a comprehensive range of technological products with magnetic tickets, phone cards, lottery tickets, promotional prints, access control tickets and security documents. The production plant is located in Serra/ES Brazil, with facilities that extend to 5.400 m² compliant with the highest standards of security and quality demanded by the market. Nowadays, FORMASET has customers in South and Central Americas.
IT | 2010-04-26
Maeglin Software annonce la signature de trois partenariats de distribution avec Sagem-Orga, ZTE, et SAB Communication
Paris, le 26 avril 2010 - Maeglin Software, société spécialisée dans le développement et la commercialisation de services innovants pour mobiles, vient de signer trois partenariats de distribution avec Sagem-Orga, un des leaders mondiaux de la carte à puce, ZTE, un des leaders mondiaux des équipements télécom, et SAB Media & Communication, un des leaders des media et des nouvelles technologies au Moyen-Orient.
Trois acteurs majeurs des télécommunications
Dans les trois cas, ces acteurs majeurs du monde des télécommunications ont choisi Maeglin Software comme leur partenaire de référence dans le domaine du partage, de la sécurisation et de la sauvegarde des contenus mobiles. Grâce à la suite de produit Pleex, ces sociétés peuvent étendre leur gamme de service et ainsi répondre, grâce à Pleex, aux appels d’offres de leurs clients opérateurs.
Sagem-Orga Gmbh, filiale de Sagem Sécurité, groupe Safran, est un leader mondial de la carte à puce et carte SIM. Son portefeuille de produits inclus équipement, logiciels et services de conseil, en particulier dans le secteur des télécommunications. La société emploie 2 100 collaborateurs au niveau mondial.
ZTEest l’un des leaders mondiaux des équipements télécom. Avec un chiffre d’affaire 2009 de 6,6 milliards d’Euros et 62 000 employés dans le monde, les équipements et solutions de ZTE sont déployés chez plus de 500 opérateurs dans 140 pays et régions.
SAB Media & Communication est l’une des sociétés opérationnelles de SAB Holding. SAB M&C est présent à travers le Moyen-Orient, dans les nouvelles technologies et chez les opérateurs grâce entre autre à ses participations dans TechnoGroup et TechnoWireless.
Suite complète de sauvegarde, partage, transfert et protection de contenu mobile
Aussi bien Sagem-Orga, ZTE que SAB Media & Communication commercialiseront la suite complète de services mobiles Pleex. La Pleex Suite est un ensemble d’éléments logiciels qui peuvent être combinés pour créer des services à valeur ajoutée (VAS) innovants. Cette suite logicielle inclue :
· PleexBackup, pour permettre aux utilisateurs de mobiles de sauvegarder, restaurer, agréger et gérer tous leurs contenus mobiles
· PleexShield, pour supprimer ou bloquer l’accès à distance du contenu de son téléphone en cas de perte ou de vol
· PleexSocial, pour publier ses photos, vidéos et commentaires depuis son mobile vers les réseaux sociaux
· PleexMigrator, pour faciliter le transfert de ses contacts d’un téléphone à un autre en cas d’achat d’un nouveau mobile ; la solution idéale pour les distributeurs et les e-commerçants
Croissance soutenue en 2010
Ces partenariats vont multiplier la croissance de Pleex, qui affiche déjà plus d’un millions d’inscrits et 35 millions de contacts sauvegardés par ses clients. Cette croissance s’explique par le fort développement commercial de Pleex en France (signature de l’assureur April Solutions et des chaines Téléphone Store et Point Service Mobiles) et à l’étranger (signature de l’opérateur polonais P4 / Play Mobile, et des distributeurs portugais Ensitel, espagnol Internity, et sud-africain Ignition Group). Elle s’explique aussi par le nombre croissant de terminaux supportés : plus de 2 000 terminaux sont compatibles Pleex à ce jour, dont les terminaux Androïd et iPhone. La croissance de Pleex est aussi due à la robustesse de ses solutions et à la pertinence de son offre élargie.
MAEGLIN SOFTWARE est une société spécialisée dans le développement et la commercialisation de services pour mobiles. Cette Jeune Entreprise Innovante (JEI) implantée à Paris et à Montpellier a été fondée en 2006. MAEGLIN est financée par CDC Innovation, Innovacom, Cap Décisif et plusieurs business angels et bénéficie du soutien d’OSEO, de LRI (Languedoc Roussillon Incubation) et de la Région Languedoc-Roussillon. Maeglin est accompagnée par le CEEI de Montpellier. Pour en savoir plus www.maeglin.com
IT | 2010-04-20
Maeglin Software annonce la signature de deux nouveaux clients
Paris, le 20 avril 2010 - Maeglin Software, société spécialisée dans le développement et la commercialisation de services innovants pour mobiles, vient de signer deux nouveaux clients : l’opérateur P4 / Play Mobile en Pologne et le distributeur Ignition Group en Afrique du Sud.
Des clients en forte croissance
Avec 3,5 millions d’abonnés l’opérateur polonais P4 / Play Mobile est l’opérateur mobile affichant la plus forte croissance en 2009 sur son marché. L’opérateur a choisi de commercialiser les solutions PleexBackup et PleexSocial sous la marque Pleex. Une campagne marketing multi-canal accompagne le lancement du service. Les clients peuvent accéder au service par le Web en allant sur http://play.pleex.com.
Ignition Group est un des leaders sud-africains de la distribution directe et du télémarketing. La société commercialise les offres des trois opérateurs sud-africains, MTN, Vodacom et CellC, ainsi que celles du MVNO Virgin Mobile. Créé il y a quatre ans, Ignition Group affiche déjà un chiffre d’affaire de plus de 100 millions d’euros. Les solutions PleexBackup et PleexSocial seront commercialisées en marque blanche par plusieurs centaines de télé-conseillers du groupe Ignition. « Nous avons choisi Maeglin Software et Pleex pour la robustesse et la flexibilité de leurs solutions et la grande couverture de terminaux que Pleex fournit. Nous avons hâte de proposer Pleex à nos clients, à un moment où tous les yeux se tournent vers l’Afrique du Sud » affirme Sean Bergsma, fondateur et P-DG de Ignition Group.
Une croissance soutenue pour Maeglin Software en 2010
Ignition Group et P4 / Play Mobile vont contribuer à la croissance de Pleex, qui affiche déjà plus d’un millions d’inscrits et 35 millions de contacts sauvegardés par ses utilisateurs. Ces nouveaux clients viennent rejoindre les clients de Pleex en France, dont l’assureur April Solutions et les chaines Téléphone Store et Point Service Mobiles, et à l’étranger, dont les distributeurs portugais Ensitel, et espagnol Internity (groupe Avenir Telecom). Comme eux, Play Mobile et Ignition Group ont été séduits par le nombre important de terminaux supportés (plus de 2 000 terminaux sont compatibles Pleex à ce jour, dont les terminaux Androïd et iPhone), la robustesse de ses solutions et la pertinence de son offre élargie.
MAEGLIN SOFTWARE est une société spécialisée dans le développement et la commercialisation de services pour mobiles. Cette Jeune Entreprise Innovante (JEI) implantée à Paris et à Montpellier a été fondée en 2006. MAEGLIN est financée par CDC Innovation, Innovacom, Cap Décisif et plusieurs business angels et bénéficie du soutien d’OSEO, de LRI (Languedoc Roussillon Incubation) et de la Région Languedoc-Roussillon. Maeglin est accompagnée par le CEEI de Montpellier. Pour en savoir plus www.maeglin.com
Life Science | 2010-04-15
Positive Phase III Diabetes Data with Lixisenatide Announced by Zealand Pharma’s Partner sanofi-aventis
Copenhagen, 15 April 2010
Zealand Pharma A/S, the biopharmaceutical company dedicated to the discovery and development of innovative peptide-based drugs, is pleased to note today that sanofi-aventis, its partner, has announced the positive results of the first, placebo-controlled study of the GetGoal Phase III clinical trial program with Lixisenatide, a novel, once daily GLP-1 agonist, for the treatment of Type-2 diabetes (T2DM) licensed from Zealand Pharma.
The key highlights of the announcement are:
· Phase III study endpoints with Lixisenatide in diabetes successfully met in first reported study
· Improved glycemic control in T2DM patients dosed once daily as monotherapy
· Lixisenatide was generally well tolerated with no significant adverse events
· Complete study findings submitted for presentation at EASD in September 2010
· Phase III program with the combination of Lixisenatide/Lantus® expected to commence in 2010 – Lantus® is the number-one sold insulin in the world in both sales and units (source: IMS, 2009 sales)
Commenting on today´s announcement David Solomon, Chief Executive Officer and President of Zealand Pharma, said: “We are delighted to note today’s announcement from our strong partner, sanofi-aventis, regarding the first successful Phase III results from the GetGoal study for Lixisenatide. These results represent a significant achievement for Zealand Pharma, and for patients with T2DM. We look forward to the ongoing clinical development of Lixisenatide by sanofi-aventis and are extremely excited about the future initiation of new Phase III studies of Lixisenatide in combination with Lantus® which are expected to commence later this year.”
The announcement issued by sanofi-aventis is shown below:
Once Daily Lixisenatide (AVE 0010) Given as Monotherapy Successfully Meets Phase III Study Endpoints in Diabetes
- Lixisenatide significantly reduced HbA1c vs placebo with more patients achieving HbA1c <7%
- Significant effect on postprandial glucose
Paris, France – April 15, 2010 – Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the results of the first, placebo-controlled study of the GetGoal Phase III clinical trial program showed lixisenatide (AVE0010), a once daily GLP-1 agonist, significantly reduced HbA1c vs. placebo with more patients achieving HbA1c<7% and improved glycemic control in adult patients with type 2 diabetes.
The complete study findings have been submitted for presentation at the 46th Annual Meeting of the European Association for the Study of Diabetes (EASD), in Stockholm, Sweden, in September 2010.
“Developing new diabetes treatments, like lixisenatide, and helping patients achieve diabetes control is paramount to tackling the growing diabetes epidemic,” said Dr. Marc Cluzel, Executive Vice-President, R&D, sanofi-aventis. “We are pleased with the top-line results from our first Phase III study of this novel, oncedaily GLP-1 agonist and are looking forward to sharing the full results later in the year.”
The 12-week study involved 361 patients with type 2 diabetes not currently receiving glucose-lowering therapy and with HbA1c between 7 and 10%. Patients were randomized to one of four once-daily treatment regimens: lixisenatide twostep titration (10 ug QD for 1 week, 15 ug QD for 1 week then 20 ug QD; n=120),lixisenatide one-step titration (10 ug QD for 2 weeks then 20 ug QD; n=119), placebo two-step titration (n=61), or placebo one-step titration (n=61).
Baseline characteristics were similar among groups in terms of mean age (53.7 ± 10.5 years), diabetes duration (2.5 ± 3.4 years) and HbA1c (8.04 ± 0.9%). HbA1c was significantly reduced in both lixisenatide titration groups versus placebo, and significantly more patients in the lixisenatide groups achieved HbA1c < 7% (46.5 to 52.2% versus 26.8%). as compared to placebo. Lixisenatide also significantly improved fasting plasma glucose and two-hour post-prandial glucose with a pronounced decrease in 2-hour post-prandial glucose excursion.
Lixisenatide was generally well tolerated. The most common adverse event was, as expected with this class of drugs, nausea occurring in 20 to 24% of lixisenatide-treated patients and 4% of placebo patients. The incidence of symptomatic hypoglycemia was low (1.7%) and similar in the lixisenatide and
placebo groups.
About Lixisenatide (AVE 0010)
Lixisenatide, a GLP-1, Glucagon-like peptide-1 agonist, is under development for the treatment of patients with type 2 diabetes mellitus. In the Phase IIb study, once-a-day dosing with lixisenatide was shown to be effective in lowering blood sugar with a good tolerability.
The Phase III GetGoal clinical trial program for lixisenatide started in May 2008. It is designed as multicentre, randomized placebo or active-controlled studies and has enrolled more than 4500 patients. The enrollment of the eight other studies of the GetGoal Phase III program assessing efficacy and safety of lixisenatide in adult patients with type 2 diabetes mellitus treated with various oral antidiabetic agents or insulin was completed at the end of 2009. A Phase III program with the combination of lixisenatide / Lantus® (insulin glar! gine [rDNA] injection) is expected to start later this year.
About Diabetes
Diabetes is a chronic, widespread condition in which the body does not produce or properly use insulin, the hormone needed to transport glucose (sugar) from the blood into the cells of the body for energy. More than 230 million people worldwide are living with the disease and this number is expected to rise to a staggering 350 million within 20 years. It is estimated that nearly 24 million Americans have diabetes, including an estimated 5.7 million who remain undiagnosed. At the same time, about 40 percent of those diagnosed are not achieving the blood sugar control target of HbA1c <7 percent recommended by the ADA.The HbA1c test measures average blood glucose levels over the past two- to three-month period.
About sanofi-aventis
Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofiaventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
About Zealand Pharma A/S
Zealand Pharma A/S is a biopharmaceutical company dedicated to the discovery and development of innovative peptide-based drugs. Zealand is one of the leaders within the peptide area, a growing market with significant drug development activities including treatment of diabetes, obesity, gastro-intestinal, metabolic and cardiovascular diseases. All of Zealand’s products target diseases and symptoms of significant unmet clinical need and commercial potential.
Since 1999, Zealand’s scientists have built a pipeline that includes five compounds in clinical development, four of which have been out licensed, three of these to major pharmaceutical companies (sanofi-aventis, Wyeth (now Pfizer) and Helsinn Healthcare). All Zealand’s compounds emerge from Zealand’s own drug discovery.
· Lixisenatide (AVE0010/ZP10), a pharmaceutical agent for the treatment of T2DM, has been out-licensed to sanofi-aventis, which is the world’s third largest pharmaceutical corporation with a strong Diabetes franchise.
· GAP-134/ZP1609; a gap junction modifier that prevents both ventricular and atrial arrhythmias in animal models. With its oral formulation, the molecule represents a novel paradigm for the potential chronic prevention of atrial arrhythmias. US based pharmaceutical giant Wyeth Pharmaceutical (now Pfizer) has finalized a Phase I trial in the US.
· ZP1846 is an innovative treatment for prevention of chemotherapyinduced diarrhea, which may prevent discontinuation and dose modification during cancer chemotherapy. A Phase I clinical trial has been
conducted in the US. The compound has been partnered with Helsinn Healthcare SA.
· ZP1848 is a novel paradigm for the treatment of Inflammatory Bowel Diseases (e.g. Crohn’s Disease). The compound has completed Phase I clinical development in the US.
· AP214/ZP1480 for Post-surgical Organ Failure, partnered with Action Pharma, currently in clinical Phase II development.
In addition, Zealand has a rich and broad portfolio of pre-clinical projects targeting a variety of disease areas, including osteoporosis and obesity-related Diabetes.
Zealand Pharma A/S is based in Copenhagen. The Company’s investors include LD Pensions, Dansk Erhvervsinvestering and Sunstone Capital as well as the leading international biotech investors CDC Innovation and Allianz Private Equity (both in Paris) and LSP (Amsterdam).
IT | 2010-04-10
Cooperation between Novaled and Ingo Maurer on transparent OLED Lamps
Dresden, Germany 10th April 2010
Ingo Maurer, internationally renowned designer and producer of exceptional lamps and lighting systems, will exhibit two OLED lamps which are the result of joint efforts with Novaled on the Light + Building trade show in Frankfurt. Novaled AG, a pioneer in OLED Lighting- and Display-Technology, has developed some transparent, highly efficient OLED modules for this purpose.
Ingo Maurer will present the pendant lamp “Flying Future” as well as the table lamp “4 x 4 is 34” at the Light + Building Frankfurt, both of which are equipped with Novaled OLEDs. Specific for these OLEDs made on glass substrates is the transparent nature in the off-state. With this feature the organic LEDs open up unimagined freedom of design, which cannot be realized with any other light source.
„The collaboration with one of the leading light designers worldwide and a forerunner in the usage of the OLED technology is both a great joy and a privilege for Novaled”, says Gerd Günther, CMO of Novaled AG. “These Ingo Maurer lamps are illustrating very well that first commercial OLED products can be realized already today”
„4 x 4 is 34 is a game with squares -as a geometrical shape but also with the number of sides, the symmetry“, states Ingo Maurer. “The mobility of the four light elements enables the user to influence the actual shape of the lamp. Flying Future is the realization of a long-cherished wish of mine”, admits Ingo Maurer. “Lightness and light, the almost amorphous shape of a kerchief floating in the air and now in addition the transparency of the OLEDs. The freedom of design, the novel stylistic elements made possible by OLEDs are a fantastic and exciting gift for us designers”, states Ingo Maurer. ”The cooperation with Novaled was very inspiring and exciting. When visiting Novaled in Dresden, one feels the power and spirit of this company.“
The Novaled OLEDs emit homogeneous, pleasantly natural white light. Approximately about 2/3 of it are emitted forward through the glass substrate, whereas the remaining 1/3 are emitted to the backside. Flying Future is using 90 “Wing” OLEDs with an active area of 30 cm² and the “4 x 4 is 34” integrates 4 “Quadro” OLEDs with a segmented light emitting area of 100 cm².
Visitors are very welcome to experience for themselves the beauty and the creative potential of the Novaled OLEDs and the Ingo Maurer lamps at the trade show booth 1.2, H18. Additional OLED lamps, light sculptures and OLED signage are being exhibited by Novaled at their booth in Hall 4.1, J51.
about Ingo Maurer
Ingo Maurer, born 1932, started to design exceptional lamps and lighting systems in 1966, which his company produces and distributes worldwide. He develops concepts and spectacular one-offs for private and public buildings with his team. Bulb (1966), the low-voltage halogen system YaYaHo (1984) and Lucellino (1992), a winged light bulb, are among his best-known designs. A number of his works have been included in permanent design collections as MoMA, New York. In 2010 Ingo Maurer received the Design Award of the Federal Republic of Germany.
about OLEDs
OLEDs (organic light-emitting diode) are semiconductors that are made of thin organic material layers that measure just a few nanometers in thickness. They emit light in a diffuse way to form an area light source. This disruptive technology represents an entirely new approach for architects, designers, system integrators, planners and luminaire makers when working with light. OLED lighting has a dual nature, which means it can function both as a lamp and a luminaire. OLEDs herald the future of a vast array of completely new lighting applications and by combining color with shape, OLEDs will create a new way of decorating and personalizing surroundings with light. Furthermore, organic LEDs will make a significant contribution to sustainability due to their energy efficiency, environmentally friendly materials and reduced packaging requirements.
about Novaled
Novaled AG is a world leader in the OLED field and specializes in high efficiency long lifetime OLED structures and is an expert in organic electronics. The company is known for its Novaled PIN OLED® technology, its proprietary OLED materials and the customized OLED products and services. Novaled has developed long term partnerships with major OLED producers throughout the world. Based on more than 400 patents granted or pending, Novaled has a strong IP position in the field of OLED technology, and was named No. 1 in a list of ‘up and coming’ world market leaders by the German newspapers Handelsblatt and Wirtschaftswoche. Its main investors include eCAPITAL, Crédit Agricole Private Equity, TechnoStart, TechFund and CDC Innovation.
IT | 2010-04-07
Gerd Günther joins Novaled Management Board
Gerd Günther, Novaled Vice President Marketing & Sales, is appointed member of the Management Board of the Company as per April 1st, 2010
Dresden, Germany, 7th April 2010
Gerd joined Novaled in March 2005 as VP M&S. Since Novaled has continuously developed its business and established deep partnerships with key Corporate’s around the world dealing with OLED for display and lighting.
In 1989 Gerd Günther accomplished his diploma in business administration at the Nuremberg Hochschule, with specialisation in Marketing. After having worked two years as Marketing Assistant at Medicare Pfrimmer in Erlangen, Gerd Günther joined in 1991 Grundig AG in Fuerth, starting an impressive career as “Product Manager for Portable Audio”.
Three years later he took over the position of the “General Manager of the Grundig Hong Kong Office”, where under his responsibility the Business Unit Portable Audio was developed into high profitability. Having returned to Fuerth in 1997, Gerd Günther held the functions “Head of the Group Marketing Audio/Hifi”, “General Manager Marketing Sound and Car Audio” as well as “Director Marketing, Consumer Electronics”, driving the product management and sales activities of the Consumer Electronic division.
“Novaled has demonstrated its capacity to become a recognized OLED world leader in the past years” says Thilo von Selchow, Novaled Chairman, “with the OLED display market taking off and the promising OLED lighting in front of us the company would develop its business in the coming years. It is the appropriate time for Gerd to join the Management Board”.
“I am delighted to have Gerd joining the Management Board” says Gildas Sorin, Novaled CEO “since his arrival at Novaled Gerd has demonstrated his capability to develop the business of the company. As member of the Management Board I am very confident that he will reinforce his contribution to the Novaled growth.”
about OLEDs
OLEDs (organic light-emitting diode) are semiconductors made of thin organic material layers of only a few nanometers thickness. They emit light in a diffuse way to form an area light source. In a fast growing display market OLEDs are key part of a revolution: the dream of paper-thin, highly efficient displays with brilliant colors and great flexibility in design. OLEDs represent the future of a vast array of completely new lighting applications. By combining color with shape, organic LEDs will create a new way of decorating and personalizing surroundings with light.
about Novaled
Novaled AG is a world leading company in the OLED field specialized in high efficiency long lifetime OLED structures and an expert in synthetic and analytical chemistry. The company offers complete solutions to the organic electronic markets, commercializing its Novaled PIN OLED® technology along with its proprietary OLED materials. Novaled has developed long term partnerships with major OLED players worldwide. Based on more than 400 patents granted or pending, Novaled has a strong IP position in OLED technology, and was named No. 1 on a list of coming world market leaders by the German newspapers Handelsblatt and Wirtschaftswoche. Main investors are eCAPITAL, Crédit Agricole Private Equity, TechnoStart, TechFund and CDC Innovation. For details please visit www.novaled.com.
IT | 2010-04-01
Marseilles Provence Metropolis offers full contactless ticketing with ASK
ASK contactless cards and tickets selected for the new ticketing system in the city
Sophia-Antipolis, April 1st 2010: ASK, leader in contactless technology for public transport, announces that the company has been selected by Marseilles region to supply all contactless transport media. Transpass card will replace subscribers’ cards while contactless paper tickets will address occasional users.
Focus on interoperability
The Marseilles Provence Metropolis Urban Community (CUMPM) and the Bouches du Rhône County Council wanted to implement what was best in terms of transport ticketing and network. Transpass contactless card will be used as a sole medium on all transportation modes of the area (Metro, tramway, bus, bikes, and sea shuttles) and within the 18 towns and cities of the CUMPM. The card is meant to be interoperable with the other regional networks such as the County Council and SNCF (French railways operator).
ASK contactless paper tickets will replace such current media as Liberty card or 5 travels cards and in the long term Solo tickets.
These new contactless media should boost the usage of public transport, strengthen the territory’s identity and increase travelers’ loyalty.
“Apart from the contactless cards offered for subscribers, Marseilles area is the first French metropolis to implement electronic tickets for the millions of its occasional users on a large scale, Amand Cochet, VP Marketing at ASK, says. We are pleased to see that the contactless paper tickets ASK invented in 2000 will make it easier for PACA region users to travel. Marseilles will no doubt be a flagship for other cities either in France or abroad.”
ASK contactless technology already in the region
Travelers in the PACA region (Provence and Riviera region) have already experienced contactless ticketing with ASK dual interface cards (contact/contactless) and contactless paper tickets.
Nice, ASK first client, was the first city in the world to launch a dual interface card on its network in 1998. Today, ASK contactless cards are in most public transport travelers’ pockets in the South of France, whether they be in Aix en Provence, Draguignan, Antibes or Nice and they can be used on all transport modes including self service bike rental…
About ASK
ASK, with over 160 million contactless products in circulation in more than 50 countries, is a worldwide leading provider of a full range of contactless products including smart cards, smart tickets, smart adhesive labels, readers, inlays for electronic passports or contactless smart cards and eDocuments. ASK is ISO9001 certified and holds a portfolio of 55 patents to date. ASK is a France-headquartered company with worldwide customers, and subsidiaries in Singapore, China, India, Brazil, Mexico and the US.
Life Science | 2010-03-16
Cytheris Announces Publication of Preclinical Study in Journal of Immunology Showing Interleukin-7 Promotes T Cell Viability, Trafficking, and Functionality While Improving Survival in Sepsis
Study indicates rhIL-7 blocks sepsis-induced depletion of CD4 and CD8 T cells, enhances lymphocyte recruitment and prevents sepsisinduced loss in immunity leading to improved survival
Paris (France) – March 16, 2010 – Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced publication of data from a preclinical study in a clinically relevant animal model of sepsis showing that recombinant human Interleukin-7 (rhIL-7) treatment not only restores T cell trafficking and function, but also translates into improved survival. Sepsis, a highly lethal disorder which occurs during severe overwhelming infection, is the most common cause of death in most intensive care units in developed countries, annually striking an estimated 750,000 people in the United States alone, resulting in the death of more than 220,000 people per year.
The paper entitled “IL-7 Promotes T Cell Viability, Trafficking, and Functionality and Improves Survival in Sepsis” is prepublished online in The Journal of Immunology, the journal of The American Association of Immunologists (Jacqueline Unsinger, Margaret McGlynn, Kevin R. Kasten, Andrew S. Hoekzema, Eizo Watanabe, Jared T. Muenzer, Jacquelyn S. McDonough, Johannes Tschoep, Thomas A. Ferguson, Jonathan E. McDunn, Michel Morre, David A. Hildeman, Charles C. Caldwell, and Richard S. Hotchkiss, March 3, 2010; doi:10.4049/ jimmunol .0903151).
The study strongly supports the belief that rather than being an uncontrolled inflammatory response, sepsis is the result of extensive apoptosis-induced depletion of immune effector cells. This explains the failure of the numerous sepsis trials conducted with agents that block the inflammatory cascade, leading investigators to question whether death in patients with sepsis results from uncontrolled inflammation. Three autopsy studies of patients who died of sepsis have confirmed findings in animal models by showing massive loss of T and B lymphocytes and dendritic cells.
“Based on this study, rhIL-7 appears to be a particularly attractive therapy for this indication because it ameliorates many of the key pathophysiologic processes that are believed to be central to the lethality of sepsis,” said Richard S. Hotchkiss, MD, Department of Anesthesiology, Washington University School of Medicine and lead investigator on the study. “Specifically, rhIL-7 blocks sepsis-induced depletion of CD4 and CD8 cells, enhances lymphocyte recruitment, prevents the sepsis-induced loss in immunity as evidenced by preserved delayed-type hypersensitivity response, does not exacerbate the proinflammatory response in sepsis, and clearly improves survival.”
By demonstrating that treatment with IL-7 reverses fundamental immunologic defects in sepsis, this study is relevant to treatment approaches in other patient populations where acute lymphopenia is a critical symptom. As described in a seminal paper by Brenchley JM (2006)1, during HIV infection, just as in sepsis, amounts of microbial products and inflammatory cytokines are increased in the patient’s bloodstream due to gut bacterial “seepage” from a compromised GI tract. In addition to direct viral damage, this condition is associated with systemic immune activation, which induces T cell dysfunction contributing to the apoptotic effects and accompanying marked decline in CD4 T cell numbers during HIV
infection. This is a strong argument for therapeutic strategies aimed at repairing the gut mucosal damage and preventing microbial translocation and hyperimmune activation in the treatment of both HIV and sepsis patients.
“In their rationale for the use of IL-7 in treatment of sepsis, Unsinger J et al reinforce the same key pathogenesis mechanism supporting T cell activation in HIVinfected, HAART treated, Immune Non Responding (INR) patients who have been the subject of ongoing clinical investigations utilizing rhIL-7,” said Michel Morre, DVM, President and CEO of Cytheris. “This mechanism is directly linked to the persistent mini sepsis originating in the T cell depleted gut mucosa of the INR population and the fact that IL-7 not only repopulates the mucosa, but also blocks a massive acute sepsis model as shown in the Journal of Immunology study, may help to explain a crucial element in the clinical outcome in this specific HIV patient subpopulation.”
About the Study
Sepsis is a highly lethal disorder characterized by widespread apoptosis-induced depletion of immune cells and the development of a profound immunosuppressive state. There is compelling evidence from animal models that the apoptosis-induced loss of immune cells is a critical factor in the immunosuppression and subsequent mortality frequently associated with the condition. The assertion that apoptosis is decisive in sepsis-induced mortality is supported by work showing that a variety of antiapoptotic strategies improve overall animal survival in this lethal disorder.
In this study, recombinant human IL-7 (rhIL-7) efficacy and potential mechanisms of action were tested in a murine peritonitis model. Studies at two independent laboratories showed that rhIL-7 markedly improved host survival, blocked apoptosis of CD4 and CD8 T cells, restored IFN-γ production, and improved immune effector cell recruitment to the infected site. Importantly, rhIL-7 also prevented a hallmark of sepsis (i.e., the loss of delayed-type hypersensitivity), which is an IFN-γ– and T cell-dependent response. Mechanistically, rhIL-7 significantly increased the expression of the leukocyte adhesion markers LFA-1 and VLA-4, consistent with its ability to improve leukocyte function and trafficking to the infectious focus. rhIL-7 also increased the expression of CD8. The potent antiapoptotic effect of rhIL-7 was due to increased Bcl-2, as well as to a dramatic decrease in sepsis-induced PUMA, a
heretofore unreported effect of IL-7.
About Sepsis
Sepsis is defined as a clinical syndrome characterized by the presence of both infection and a systemic inflammatory response. The patient populations most susceptible to sepsis include those with the following characteristics: age younger than 1 year or older than 65 years, chronic illness, immunosuppression, broadspectrum antibiotic use, and exposure to infection associated with surgical and invasive procedures. The treatment of sepsis is often focused on supporting failing organ systems with interventions including fluid replacement, airway management, antibiotic therapy, and use of vasopressors. Current clinical advances in the treatment of sepsis include therapy with activated protein C in select subsets of patients, control of blood glucose, and early goal-directed therapy to treat the cellular oxygen deficit. Between the US and the EU there are estimated to be more that 1.5 million episodes of sepsis per year with a 25-30% mortality rate and an annual cost to western economies of €45B. In fact, severe sepsis takes more lives than breast, colon/rectal, pancreatic, and prostate cancer combined.
About Interleukin-7 (CYT107)
Recombinant human interleukin-7 (CYT107) is a critical immune-modulator for immune T-cell recovery and enhancement. As a growth factor and cytokine physiologically produced by marrow or thymic stromal cells and other epithelia, IL-7 has a critical and, at some steps, a non-redundant stimulating effect on T lymphocyte development, notably on thymopoïesis and, downstream from the thymus, on homeostatic expansion of peripheral T-cells.
A first-generation form of rhIL-7 was shown in pre-clinical and Phase I studies in oncology and HIV-infected patients to be well tolerated in repeated dose trials, with long-lasting increases in both CD4 and CD8 T cells. CYT107 is a second-generation rhIL-7 product made by Cytheris via a recombinant mammalian cell culture system.
Clinical trials conducted on more than 140 patients in Europe, North America and Taiwan have demonstrated the potential of IL-7 to expand and protect CD4+ and CD8+ T-cells.
Currently, Cytheris is conducting multiple international investigations of IL-7 in HIV, HBV, HCV, idiopathic CD4 lymphocytopenia (sponsored by NIAID/NIH) and cancer, the latter including an NCI/NIH-sponsored study of IL-7 in combination with dendritic cell vaccines in a pilot study of tumor vaccination in children, and a study designed to restore CD4+ and CD8+ counts following T-cell depletion due to bone marrow or peripheral blood stem cell transplant (being conducted at the Memorial Sloan-Kettering Cancer Center in New York City).
About Cytheris – www.cytheris.com
Cytheris SA is a privately held clinical-stage biopharmaceutical company focused on research and development of new therapies for immune modulation. These drugs aim at reconstituting and enhancing the immune system of patients suffering from cancer, chronic viral or bacterial infections such as HCV, HBV and HIV, or lymphodepleting treatments such as chemotherapy, radiotherapy, bone marrow transplantation (BMT) and hematopoietic cell transplantation (HCT). The company operates from its headquarters and laboratories in Issy-les-Moulineaux, a suburb of Paris, and its U.S. subsidiary in Rockville, Maryland.
(1) Brenchley JM, et al. 2006. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 12 (12) Dec 1365-1371.
IT | 2010-03-16
6WIND Provides 10x Acceleration of Packet Processing Functions on New Multi-Core Intel® Platforms
6WINDGate™ Software Helps Maximize Packet Processing Performance on Intel® Xeon® Processor EC5549 and Intel® Xeon® Processor E5645
March 16, 2010 – PARIS, France – 6WIND, the leading provider of high-performance packet processing software for embedded systems, today announced support for the new multi-core, embedded Intel® Xeon® processor EC5549 and Intel® Xeon® processor E5645. Using the 6WINDGate software, system developers increase the packet processing performance of their networking, telecommunications and security products by up to 10x compared to a standard Linux implementation, while reusing their existing application software and accelerating their time-to-market.
A member of the Intel® Embedded Alliance, 6WIND counts many of the world’s leading networking and telecommunications companies as its customers or partners. This includes telecommunications equipment manufacturers, operating system vendors and embedded software suppliers. Two-thirds of the largest telecommunications equipment suppliers use the company’s software to maximize the packet processing performance of their systems.
The 6WINDGate software provides best-in-class packet processing performance for Intel platforms. When compared to an implementation based on a standard Linux networking stack, systems using 6WINDGate configured with the “6WINDGate SDS” profile will achieve a 7x performance improvement on a four-core Intel® Xeon® processor EC5549 platform and a 10x performance improvement on a six-core Intel® Xeon® processor E5645 platform. The “6WINDGate SDS” profile is optimized for platforms in which the networking Fast Path runs on dedicated cores without the overhead of a Linux-based Slow Path.
6WINDGate’s architecture removes the complexity of integrating high-performance packet processing with the Linux environment, because it fully synchronizes the Fast Path and Linux, while preserving Linux APIs. It includes complete Layer 2 through Layer 4 embedded networking features (routing, IPsec, firewall, QoS, NAT, multicast…), reducing development time by as much as 70 percent. 6WINDGate also maximizes software reuse, so that legacy applications previously running on single-core architectures can quickly and with minimal or no modifications migrate to multicore architectures while achieving maximum performance. 6WIND’s environment incorporates an XML-based management interface that eases the integration of networking applications and customers’ value-added features.
6WINDGate will be available with full 6WINDGate SDS profile support for Intel Xeon processor EC5549 and Intel Xeon processor E5645 in mid-2010. Additionally, an early release is available now configured with the “6WINDGate EDS” profile (optimized for platforms in which the Fast Path runs as a Linux kernel module). In order to minimize their time-to-market, customers are able to start their software development now using the current 6WINDGate EDS-based release, then migrate to the 6WINDGate SDS version later to maximize the performance of their product, with no changes to their application software.
“The Intel® Xeon® processor EC5540 and Intel® Xeon® processor E5645 based platforms provide high-performance solutions for a wide range of communications applications in which packet processing functions comprise the majority of the workload”, said Eric Carmès, CEO of 6WIND. “Our 6WINDGate software is ideal for accelerating these systems and we are pleased to be providing a high-performance, proven solution that brings a compelling performance advantage to Intel’s customers.”
“The multi-core architecture of the latest Intel® Xeon® processor 5600 series and the Intel® Xeon® processor C5500 series comprise ideal platforms for packet processing-based systems,” said Stephen Price, Director of Marketing at Intel Corporation. “Many of our customers are developing packet processing-based products using these platforms and 6WIND’s software will help them maximize the performance of their products and potentially accelerate their time to market.”
The system-level performance enabled by 6WIND’s software creates exciting new opportunities for independent software companies as well as for Intel customers. While retaining full compatibility with standard Linux APIs, the 6WIND solution raises the performance of multi-core Intel® platforms to a level that enables the development of new applications in areas such as network security and advanced IP services, which require high-speed packet processing within constrained power budgets. Since the high-performance 6WINDGate engine is transparent to application software, developers can add compelling new features to their current Linux-based applications, or create new products from scratch, all while working within standard Linux development environments and leveraging the wealth of Linux packages available in the open-source community.
The Intel® Xeon® processor 5600/5500 series, based on the latest generation Intel® microarchitecture (codenamed Nehalem), offers the first Intel Xeon processors on 32nm technology (5600 series), providing a follow-on to the Intel Xeon processor 5500 series on 45nm technology. Delivering world-class performance, these processors provide key embedded features such as extended lifecycle support along with options for thermally constrained applications while maintaining compatibility with enterprise platform configurations. The common microarchitecture and a common mechanical socket throughout both series provide investment protection and a simplified path to upgrades. The Intel Xeon 5500 series represents a leap forward in Intel Xeon processor technology by lowering power and increasing performance-per-watt through the integration of I/O into the processor. Utilizing second-generation High-k metal gate transistors, the 5600 series represents the next step in energy efficiency, performance and virtualization. All the processors in the 5600/5500 series feature Intel® Virtualization Technology for flexible virtualization, as well as Intel® QuickPath Technology. Additionally, a number of processors feature Intel® Turbo Boost Technology and Intel® Hyper-Threading Technology to deliver top performance for bandwidth-intensive applications.
About 6WIND
6WIND provides high-performance packet processing embedded software solutions used by networking, telecommunications and security companies providing equipment for converged, all-IP networks. The company’s 6WINDGate™ solution maximizes the packet processing performance of single- and multicore platforms, allowing customers to focus on their own value-added software applications and minimize their time-to-market. To ensure the availability of a complete system-level ecosystem, 6WIND partners with industry-leading suppliers of board-level products, operating systems and embedded software products worldwide. 6WIND is a privately-owned company based near Paris, France with a subsidiary in California, a sales and support office in Asia, and an R&D center in Beijing, China. For more information, visit www.6wind.com.
IT | 2010-03-16
6WIND Provides 10x Acceleration of Packet Processing Functions on New Multi-Core Intel® Platforms
6WINDGate™ Software Helps Maximize Packet Processing Performance on Intel® Xeon® Processor EC5549 and Intel® Xeon® Processor E5645
March 16, 2010 – PARIS, France – 6WIND, the leading provider of high-performance packet processing software for embedded systems, today announced support for the new multi-core, embedded Intel® Xeon® processor EC5549 and Intel® Xeon® processor E5645. Using the 6WINDGate software, system developers increase the packet processing performance of their networking, telecommunications and security products by up to 10x compared to a standard Linux implementation, while reusing their existing application software and accelerating their time-to-market.
A member of the Intel® Embedded Alliance, 6WIND counts many of the world’s leading networking and telecommunications companies as its customers or partners. This includes telecommunications equipment manufacturers, operating system vendors and embedded software suppliers. Two-thirds of the largest telecommunications equipment suppliers use the company’s software to maximize the packet processing performance of their systems.
The 6WINDGate software provides best-in-class packet processing performance for Intel platforms. When compared to an implementation based on a standard Linux networking stack, systems using 6WINDGate configured with the “6WINDGate SDS” profile will achieve a 7x performance improvement on a four-core Intel® Xeon® processor EC5549 platform and a 10x performance improvement on a six-core Intel® Xeon® processor E5645 platform. The “6WINDGate SDS” profile is optimized for platforms in which the networking Fast Path runs on dedicated cores without the overhead of a Linux-based Slow Path.
6WINDGate’s architecture removes the complexity of integrating high-performance packet processing with the Linux environment, because it fully synchronizes the Fast Path and Linux, while preserving Linux APIs. It includes complete Layer 2 through Layer 4 embedded networking features (routing, IPsec, firewall, QoS, NAT, multicast…), reducing development time by as much as 70 percent. 6WINDGate also maximizes software reuse, so that legacy applications previously running on single-core architectures can quickly and with minimal or no modifications migrate to multicore architectures while achieving maximum performance. 6WIND’s environment incorporates an XML-based management interface that eases the integration of networking applications and customers’ value-added features.
6WINDGate will be available with full 6WINDGate SDS profile support for Intel Xeon processor EC5549 and Intel Xeon processor E5645 in mid-2010. Additionally, an early release is available now configured with the “6WINDGate EDS” profile (optimized for platforms in which the Fast Path runs as a Linux kernel module). In order to minimize their time-to-market, customers are able to start their software development now using the current 6WINDGate EDS-based release, then migrate to the 6WINDGate SDS version later to maximize the performance of their product, with no changes to their application software.
“The Intel® Xeon® processor EC5540 and Intel® Xeon® processor E5645 based platforms provide high-performance solutions for a wide range of communications applications in which packet processing functions comprise the majority of the workload”, said Eric Carmès, CEO of 6WIND. “Our 6WINDGate software is ideal for accelerating these systems and we are pleased to be providing a high-performance, proven solution that brings a compelling performance advantage to Intel’s customers.”
“The multi-core architecture of the latest Intel® Xeon® processor 5600 series and the Intel® Xeon® processor C5500 series comprise ideal platforms for packet processing-based systems,” said Stephen Price, Director of Marketing at Intel Corporation. “Many of our customers are developing packet processing-based products using these platforms and 6WIND’s software will help them maximize the performance of their products and potentially accelerate their time to market.”
The system-level performance enabled by 6WIND’s software creates exciting new opportunities for independent software companies as well as for Intel customers. While retaining full compatibility with standard Linux APIs, the 6WIND solution raises the performance of multi-core Intel® platforms to a level that enables the development of new applications in areas such as network security and advanced IP services, which require high-speed packet processing within constrained power budgets. Since the high-performance 6WINDGate engine is transparent to application software, developers can add compelling new features to their current Linux-based applications, or create new products from scratch, all while working within standard Linux development environments and leveraging the wealth of Linux packages available in the open-source community.
The Intel® Xeon® processor 5600/5500 series, based on the latest generation Intel® microarchitecture (codenamed Nehalem), offers the first Intel Xeon processors on 32nm technology (5600 series), providing a follow-on to the Intel Xeon processor 5500 series on 45nm technology. Delivering world-class performance, these processors provide key embedded features such as extended lifecycle support along with options for thermally constrained applications while maintaining compatibility with enterprise platform configurations. The common microarchitecture and a common mechanical socket throughout both series provide investment protection and a simplified path to upgrades. The Intel Xeon 5500 series represents a leap forward in Intel Xeon processor technology by lowering power and increasing performance-per-watt through the integration of I/O into the processor. Utilizing second-generation High-k metal gate transistors, the 5600 series represents the next step in energy efficiency, performance and virtualization. All the processors in the 5600/5500 series feature Intel® Virtualization Technology for flexible virtualization, as well as Intel® QuickPath Technology. Additionally, a number of processors feature Intel® Turbo Boost Technology and Intel® Hyper-Threading Technology to deliver top performance for bandwidth-intensive applications.
About 6WIND
6WIND provides high-performance packet processing embedded software solutions used by networking, telecommunications and security companies providing equipment for converged, all-IP networks. The company’s 6WINDGate™ solution maximizes the packet processing performance of single- and multicore platforms, allowing customers to focus on their own value-added software applications and minimize their time-to-market. To ensure the availability of a complete system-level ecosystem, 6WIND partners with industry-leading suppliers of board-level products, operating systems and embedded software products worldwide. 6WIND is a privately-owned company based near Paris, France with a subsidiary in California, a sales and support office in Asia, and an R&D center in Beijing, China. For more information, visit www.6wind.com.
Life Science | 2010-03-15
KUROS MEETS PRIMARY EFFICACY ENDPOINT IN PHASE IIB STUDY WITH KUR-111 RESULTS PROVIDE FIRST CLINICAL PROOF OF PRINCIPLE FOR KUROS’ BIOACTIVE-BIOMATERIAL PRODUCT PLATFORM
Zurich, Switzerland, 15th March, 2010 - Kuros Biosurgery AG announced today the results of a Phase IIb clinical trial assessing the potential of KUR-111 (Viz.I-0401) in the treatment of patients with tibial plateau fractures that require fixation and grafting. The study achieved its primary efficacy endpoint, which was the demonstration of statistical non-inferiority to autograft with respect to the proportion of patients who achieved radiological fracture union at 16 weeks after grafting. This is the first large scale clinical study to demonstrate the efficacy of a product based on Kuros’ proprietary bioactive-biomaterial technologies.
The repair of tibial plateau fractures often requires the replacement of bone lost by compaction with autologous bone taken from another site in the patient. Harvesting of autologous bone has implications for the patient in terms of risk of infection and additional morbidity, as well as requiring additional surgery. KUR-111 is designed to promote bone healing that is considered to be as good as autograft, which is the gold standard in many orthopedic procedures.
KUR-111 is composed of a variant of parathyroid hormone (vPTH), fibrin sealant and hydroxyapatite/tri-calcium phosphate (HA/TCP) granules. The product is applied directly to the fracture site as a mouldable putty able to form to the shape of the bone defect. KUR-111 utilizes Kuros’ “TG-hook” technology for covalently binding vPTH into the fibrin sealant.
This Phase IIb trial is a randomized, controlled, open-label (dose-blinded), multi-center, dose-finding study. The study treated 183 patients at 30 centers across Europe and Australia. At 16 weeks, 84% of autograft treated patients and 84% of patients treated with the higher dose of KUR-111 had radiological fracture healing defined by an independent radiology panel using CT Scans at 16 weeks post surgery. In addition, a substantial difference was observed between the two doses of vPTH tested in this study, with the higher dose giving the higher efficacy (p value = 0.033). Secondary endpoints related to efficacy were consistent with the primary endpoint. For example a composite endpoint of CT scan and clinical healing gave 72% for the higher dose of KUR-111 and 64% for autograft. There were no indications of any safety issues.
Virginia Jamieson, Chief Medical Officer of Kuros, commented: “We are extremely pleased with the outcome of this study. The product was well tolerated, with good bone healing. It demonstrated similar efficacy to autograft, and it showed a difference in the bone healing response between the two concentrations of vPTH tested”. KUR-111 is the first of a family of product candidates based on Kuros’ “TG-Hook” technology that are designed to improve bone repair or to generate bone. These positive clinical results are not only supportive of this product candidate but also of others that are based on the
same or similar technologies.
Didier Cowling, CEO of Kuros, stated: “These positive results further support the strength of Kuros’ product development activities based on bioactive-biomaterial combinations. We look forward to progressing this program, and others, with our partners and to bringing products to market that make a valuable contribution to patient treatment”.
KUR-111 is licensed to Baxter International Inc. under a Collaboration and Licence Agreement which was signed in 2005. Baxter has the right under the Collaboration and Licence Agreement to assume responsibility for further development of KUR-111.
About tibial plateau fractures
The tibial plateau refers to the upper end of the shin bone that articulates with the femur in the knee joint. Tibial plateau fractures are usually the result of high impact trauma, for example those caused by falls or road traffic accidents. They are challenging fractures for the orthopaedic surgeon, as the fracture needs very careful placement of the fragments to re-establish the articular surface of the knee joint in order to prevent the development of osteoarthritis of the knee or leg axis deviations.
About Kuros
www.kuros.ch
Kuros is a biotechnology company that is focused on the development of novel biomaterials and bioactive-biomaterial combinations for trauma, wound and spinal indications. Kuros’ combination products are designed to mimic the body’s natural healing process. The products consist of fusion proteins of naturally occurring bioactive factors, covalently incorporated into fibrin or synthetic matrices. The incorporation of the biologically active molecules into the matrices aims to maximize their activity by retention at the site of action. Kuros products are designed to combine ease of application with localized delivery. Kuros has a number of methodologies to achieve the desired retention and release profiles of the biologically active molecules. Kuros’ has a diverse pipeline of product candidates with its most advanced products being in trauma and wound care. Since its creation, Kuros has raised over $100 million. The company is located in Zurich, Switzerland.
IT | 2010-03-11
German Novaled AG receives Clean Equity Award 2010
Dresden, Germany, 11th March 2010
Novaled AG -a world class provider in OLED technologies for highly efficient and environmental friendly display and lighting solutions- is winner of the CleanEquity Award 2010. H.S.H Prince Albert II of Monaco presented the award to the winner at the international conference for Cleantech Specialists ‚CleanEquity Monaco 2010’ on March, 5th.
Together with some 40 other young and promising technology companies from four different continents Novaled has been pre selected to present in front of more than 250 investment and cleantech specialists as well as politicians and journalists. By introducing Novaled’s business field, a convincing company concept and an outstanding revenue potential Novaled succeeded and won the award for Excellence in the Field of Environmental Technology Development.
"We are proud to be recognized for the successful development of our Novaled PIN OLED® technology and
the continuous growth of the company”, says Harry Boehme, CFO Novaled AG.
“Our efforts for developing highly efficient and long living solutions for the next generation display and lighting products are supported a lot by receiving the cleantech award. At the same time the award emphasizes the excellent reputation Novaled has earned among cleantech companies and investors.”
Beside Novaled there are winners in two other categories. The award for Excellence in the Field of Environmental Technology Research went to Sun Catalytix (USA). The award for Excellence in the Field of Environmental Technology Commercialization went to Oxford Catalysts.
about OLEDs
OLEDs (organic light-emitting diode) are semiconductors made of thin organic material layers of only a few nanometers thickness. They emit light in a diffuse way to form an area light source. In a fast growing display market OLEDs are key part of a revolution: the dream of paper-thin, highly efficient displays with brilliant colors and great flexibility in design. OLEDs represent the future of a vast array of completely new lighting applications. By combining color with shape, organic LEDs will create a new way of decorating and personalizing personal surroundings with light.
about Novaled
Novaled AG is a world leading company in the OLED field specialized in high efficiency long lifetime OLED structures and an expert in synthetic and analytical chemistry. The company offers complete solutions to the organic electronic markets, commercializing its Novaled PIN OLED® technology along with its proprietary OLED materials. Novaled has developed long term partnerships with major OLED players worldwide. Based on more than 400 patents granted or pending, Novaled has a strong IP position in OLED technology, and was named No. 1 on a list of coming world market leaders by the German newspapers Handelsblatt and Wirtschaftswoche. Main investors are eCAPITAL, Crédit Agricole Private Equity, TechnoStart, TechFund and CDC Innovation. For details please visit www.novaled.com.
IT | 2010-03-07
Expanded Technology Partnership to Increase Integration of 6WIND’s Multicore Embedded Networking Software with Emerson Network Power’s AdvancedTCA® Platforms
Technology Partnership Expansion Includes Integrating 6WINDGate™ Embedded Networking Software on
OCTEON™-Based Emerson Network Power Platforms; Enhanced Joint Marketing and Sales Efforts
Mountain View, California – Jan. 11, 2010 – 6WIND, the leading provider of high-performance packet processing embedded software for networking and telecommunications equipment, and Emerson Network Power, a business of Emerson and the global leader in enabling Business-Critical Continuity™, today announced an expansion of their technology partnership for joint multicore-based solutions. As part of the expansion, 6WIND will further integrate its 6WINDGate™ embedded networking software for multicore with Emerson Network Power AdvancedTCA® (ATCA®) blades based on Cavium Networks OCTEON™ processors. The first expanded integration of 6WINDGate features Emerson Network Power’s ATCA-9305, an ATCA blade based on dual OCTEON CN5860 processors and the Freescale™ Semiconductor MPC8548 management processor.
The solutions will be supported with newly enhanced sales and marketing efforts by Emerson Network Power and 6WIND, with the objective of providing customers with greater integrated solutions that can help accelerate multicorebased designs.
The ATCA-9305 is targeted at security and packet-processing applications in the wireless and telecommunications transport markets. This market includes data plane packet processing, security co-processing, video compression and pattern matching. The ATCA-9305 complies with the SCOPE recommended profile for central office ATCA systems, CP-TA rules for interoperability with ATCA shelves and the PICMG® 3.0 ATCA specifications.
The ATCA-9305 is designed in the tradition of Emerson Network Power’s ATCA product portfolio. Reliability, high availability and field maintainability are the key means for reducing operational expenses. Capital expense is lowered drastically at the system level by introducing a new class of performance density, based on state-of-the-art multicore packet processing technologies. It will use 6WINDGate embedded networking software to greatly expedite the multicore design of embedded networking functionality and integration of applications running on this multicore-based architecture.
“Our joint solutions are already in use with a variety of tier one customers helping them realize powerful networking solutions with simplified design and development processes,” commented Dick DuBois, senior vice president, embedded Computing & Power, Emerson Network Power. “Our increased collaboration will provide a broader spectrum of joint and tightly integrated solutions in terms of technology, sales and support.”
6WINDGate is 6WIND’s high-performance packet processing embedded software solution for networking and telecommunications equipment. With optimized support for multicore platforms from multiple embedded processor suppliers, 6WINDGate allows system developers to focus their design efforts on their own value-added software components, with 6WINDGate implementing the low-level packet processing and data plane functions. This allows customers to maximize the system-level performance of their platform while enjoying the ability to seamlessly scale from single-core systems to more complex multicore architectures. 6WINDGate provides several key advantages for telecommunications, security and networking equipment manufacturers, as well as for embedded processor suppliers:
• Maximizes the ability to benefit from performance gains offered by multicore processors
• Scales from one to any number of cores using simple-to-implement differing profiles
• Enables seamless integration of the multicore executive environment (MCEE) with any Linux architecture using an open and standards-based approach Emerson and 6WIND Expand Tech Partnership 2-2-2-2
• Off-the-shelf ready with a complete set of networking features expedites networking design times by as
much as 70 percent
• Complete XML-based manageability eases integration of networking, applications and value-added features
• Maximizes customers’ reuse of existing software
• Reduces development cycles and design time leading to cost reductions and creating a strong value proposition for telecommunications, security and networking equipment manufactures, and chipset providers
The ATCA-9305 uses the 6WINDGate SDS profile for highest performance. 6WINDGate provides a complete readyto- use networking solution including dual-IP networking protocols, comprehensive L2/L3 networking functions, unicast and multicast forwarding, virtual routing, tunneling, IPsec via built-in crypto processors, stateful firewall, QoS, NAT, and a VNB framework designed to easily integrate new interfaces such as WiMAX or L2 protocols. 6WINDGate can run as a pure open source or commercial Linux solution (ADS and EDS) or in conjunction with the MCEE (SDS) to provide the highest level of performance and a seamless integration into a customers’ existing Control Plane. It enables an end-to-end simplified design process for all phases, from the ability to develop a system using a simulation environment to the development and integration of applications on multicore chips and the migration of applications to multicore.
“Our joint customers will be able to realize more powerful and design-friendly solutions for a variety of applications,” said Eric Carmès, CEO of 6WIND.” This includes telecommunications infrastructure equipment such as 4G, LTE, and wired applications; enterprise gateways; security appliances; network offload engines for IP-based applications and more. We’re excited about the prospects of partnering with Emerson Network Power to jointly address a myriad of application and design needs around advanced multicore architectures.”
About Emerson Network Power
Emerson Network Power, a business of Emerson, is the global leader in enabling Business-Critical Continuity™ from grid to chip for telecommunication networks, data centers, health care and industrial facilities. Emerson Network Power provides innovative solutions and expertise in areas including AC and DC power and precision cooling systems, embedded computing and power, integrated racks and enclosures, power switching and controls, monitoring, and connectivity. All solutions are supported globally by local Emerson Network Power service technicians. For more information on Emerson Network Power’s embedded computing products and services including ATCA®, COM Express™, CompactPCI®, embedded motherboards, MicroTCA®, VMEbus and OpenSAF® for original equipment manufacturers and systems integrators in the telecommunications, industrial automation, aerospace/defense and medical markets, visit www.EmersonNetworkPower.com/EmbeddedComputing. Learn more about Emerson Network Power products and services at www.EmersonNetworkPower.com.
About 6WIND
6WIND provides high-performance packet processing embedded software solutions used by networking and telecommunications companies providing equipment for converged, all-IP networks. The company’s 6WINDGate™ solution maximizes the packet processing performance of single- and multicore platforms from several processor suppliers, allowing customers to focus on their own value-added software applications and minimize their time-tomarket. To ensure the availability of a complete system-level ecosystem, 6WIND partners with industry-leading suppliers of multicore processors, board-level products, operating systems and embedded software products worldwide. 6WIND is a privately-owned company based near Paris, France with a subsidiary in California, a sales and support office in Asia, and an R&D center in Beijing, China. For more information, visit www.6wind.com. Note: References to company, product, brand, service or similar names may be trademarks owned by their respective company. Business-Critical Continuity and Emerson Network Power are trademarks and service marks of Emerson Electric Co
Life Science | 2010-02-24
Transgenomic Licenses IP From IntegraGen to Develop Genetic Test for Autism
OMAHA, Neb. (February 24, 2010) – Transgenomic, Inc. (OTC/BB: TBIO) announced today that it has
licensed on an exclusive U.S. basis intellectual property from IntegraGen SA that will enable Transgenomic to develop and commercialize a genetic test designed to assess the risk of autism in children who have older siblings diagnosed with an autism spectrum disorder. Under the agreement Transgenomic will develop the test in the Company’s CAP-accredited and CLIA-certified laboratory, and anticipates launching the new test in the second quarter of 2010. Financial terms of the agreement were not disclosed.
“We are pleased to have the opportunity to develop and offer a genetic test to clinicians and parents that
will assist in the evaluation of children who are thought to be at high risk of being autistic,” stated Craig Tuttle, president and chief executive officer of Transgenomic. “We believe that the use of this test in conjunction with standard diagnostic tools will allow for the earlier diagnosis of autism, and importantly, the more timely initiation of treatment plans for these children. We look forward to adding this proprietary test to our growing commercial offerings.”
Autism is a developmental disorder that causes significant social, communication and behavioural challenges in children. The Centers for Disease Control and Prevention estimates that one in 110 children
in the U.S. has an autism-related disorder, and that the incidence of autism is up 57 percent from 2002 to 2006. Even though parents typically express concerns about their child's developmental progress before the age of three, the average age of diagnoses is not until 53 months. Early intervention has been shown to be effective in improving a child’s ability to develop into a competent adult. Children with a sibling who has been diagnosed with autism are at a significantly greater risk of developing the disorder.
“IntegraGen is excited about the opportunity for our technology to be commercialized by Transgenomic,”
said Dr. Bernard Courtieu, chief executive officer of IntegraGen. “We will continue our gene discovery efforts to further our understanding of autism while focusing on other diseases where molecular tests may help with patient diagnosis and disease management.”
About IntegraGen
IntegraGen (www.integragen.com) is a Biotechnology Company dedicated to gene discovery which allows for the development of molecular diagnostics products and services that provide clinicians with new tools to personalize diagnosis, treatment, and therapy. IntegraGen is focused on the prevention and proactive management of complex debilitating diseases, and dedicated to addressing the needs of patients, clinicians, and advocacy groups. IntegraGen’s Genetic Services Business also provides state of the art Genotyping Services to the research community. With discovery and intellectual property focused on Autism, Oncology and Metabolism, IntegraGen’s Core Strategy is to deliver a portfolio of high-value molecular diagnostic products and services that drive personalized healthcare solutions for complex diseases.
About Transgenomic, Inc.
Transgenomic, Inc. (www.transgenomic.com ) is a global biotechnology company specializing in high sensitivity genetic variation and mutation analysis, providing products and services in DNA mutation detection and discovery for clinical research, clinical molecular diagnostics and pharmacogenomics analyses. Its product offerings include the WAVE® Systems and associated consumables specifically designed for use in genetic variation detection and single- and double-strand DNA/RNA analysis and purification. With broad applicability to genetic research, over 1,475 systems have been shipped to customers in more than 30 countries. The SURVEYOR® Mutation Detection Kits and SURVEYOR Check-It Kit provide reagents and protocols for high sensitivity detection of mutations in DNA. In addition, HANABI automated chromosome harvesting systems improve laboratory productivity with consistent quality compared with manual methods for cytogenetic analyses. Service offerings include the Transgenomic Molecular Laboratory, which provides reference laboratory services specializing in molecular diagnostics including Mitochondrial Disorders, Oncology and Hematology, Molecular Pathology and Inherited Diseases. Transgenomic Pharmacogenomics Services is a CRO for pharmacogenomic, translational research and clinical trials.
Forward-Looking Statements
Certain statements in this press release constitute “forward-looking statements” of Transgenomic within
the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Forward-looking statements include, but are not limited to, those with respect to management’s current views and estimates of future economic circumstances, industry conditions, company performance and financial results, including the ability of the Company to grow its involvement in the diagnostic products and services markets. The known risks, uncertainties and other factors affecting these forward-looking statements are described from time to time in Transgenomic’s filings with the Securities and Exchange Commission. Any change in such factors, risks and uncertainties may cause the actual results, events and performance to differ materially from those referred to in such statements. Accordingly, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 with respect to all statements contained in this press release. All information in this press release is as of the date of the release and Transgenomic does not undertake any duty to update this information, including any forward-looking statements, unless required by law.
IT | 2010-02-03
Entrepreneurs et Investisseurs Technologies annonce l’acquisition de la société Adeon
Paris, le 3 février 2010.
CDC Innovation et Entrepreneurs & Investisseurs Capital, qui ont pour objectif commun, au travers d’Entrepreneurs et Investisseurs Technologies (« EI-Technologies »), de bâtir un groupe de spécialistes à forte valeur ajoutée dans les domaines les plus innovants du conseil et des services en systèmes d’information, annoncent l’acquisition de la société Adeon.
Adeon est une société de conseil spécialisée dans l’amélioration des processus et outils de vente et de marketing. Elle a été fondée en 2003 par Christophe RITTANO qui rejoint le Comité Exécutif de EITechnologies.
Adeon accompagne les directions métiers et la DSI de grands comptes dans toutes les phases critiques de leurs projets CRM, Business Intelligence ou Internet : du cadrage stratégique au déploiement en filiales, en passant par le challenge des besoins métiers, le choix et la mise en oeuvre de solutions ou le pilotage opérationnel du projet et des risques.
L’acquisition d’Adeon s’inscrit dans la stratégie de renforcement du positionnement de spécialiste de EI-Technologies en particulier dans les domaines du CRM et du Cloud Computing. Notre ambition est de viser une position unique de leader innovant et reconnu pour aider nos clients à tirer le profit maximal des ruptures technologiques actuelles avec les offres suivantes :
· Accompagnement des métiers et des processus transverses les plus impactés (Marketing,
Commerce, Achats, SAV, SI, Dématérialisation des processus),
· Définition de la stratégie de Sourcing des directions informatiques,
· Implémentation des innovations les plus récentes et les plus performantes en termes de Cloud
Computing et d’Open Source,
· Accompagnement des changements organisationnels et humains,
· Maintien de la qualité et de la performance des systèmes d’information grâce au Testing,
· Accroissement de la Sécurité.
Avec Adeon, le chiffre d’affaires annuel de EI-Technologies dépasse 20 M€.
A propos de CDC Innovation
Créée en 1996, CDC Innovation (www.cdcinnovation.com) est une société de venture capital basée à Paris. Avec plus de 415 M€ de fonds sous gestion, elle investit dans des entreprises innovantes en phase de premiers développements ou en phase de croissance, dans deux secteurs: les technologies de l'information et les sciences de la vie.
Son objectif est de créer de la valeur en apportant à des entrepreneurs de talent les ressources, l'expérience et le réseau nécessaires pour transformer des sociétés technologiques à haut potentiel en de véritables succès industriels.
A propos de EI-Capital
Créée en 2007 par Bechara RAAD, Jean-Arnaud de LASA et Pierre SARROLA, Entrepreneurs & Investisseurs Capital est une société d’investissement spécialisée dans l’acquisition et le management de PME en transmission. Elle élabore aujourd’hui deux regroupements sectoriels, le premier dans le domaine du conseil et des services en systèmes d’information, le second dans la fourniture de solutions technologiques pour l’immobilier.
IT | 2010-01-25
Fluidigm, IntegraGen form French Alliance
January 25, 2010 By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Fluidigm and IntegraGen today said that the firms have formed an alliance to bring Fluidigm's products to researchers in France.
Evry, France-based IntegraGen will offer services to its customers using Fluidigm's BioMark System for genetic analysis and Access Array sample preparation system for next-generation sequencing applications. In addition, IntegraGen will serve as a demonstration site for Fluidigm's technology.
"These tools complete the IntegraGen Services portfolio and put our lab at the cutting edge of genotyping and next generation sequencing capabilities," Emmanuel Martin, director of genomic services at IntegraGen, said in a statement.
Further details of the alliance were not disclosed.
IT | 2010-01-06
STMicroelectronics Pushes the Multi-Touch Screen Market and Unveils Resistive Multi-Touch Single-Chip Controller with Unrivaled Performance
Geneva, January 06 ,2010 - As the latest high-tech devices such as smartphones, mobile internet devices and netbooks adopt multi-touch touchscreens to support increasingly sophisticated ‘apps’ and games, STMicroelectronics (NYSE: STM), a world leader in microcontrollers, has introduced a very advanced multi-touch ‘resistive’ touchscreen controller chip to optimize the Bill of Materials of the electronics supporting this advanced capability. The STM32TS60 is the first member of ST’s new STMTouch family, which offers a broad portfolio of solutions including multi-touch devices and proximity and touch-key sensors.
The new multi-touch controller detects up to ten simultaneous touches with fingers, nails or stylus, enabling application designers to replace complex menu sequences with more direct and natural user controls. Actions made easier with multi-touch capabilities include browsing and selecting options, handwriting and data entry, arranging and sizing windows, picking up and dragging images, and fast and intuitive game play. Other abilities include drawing pictures, using touch pressure to adjust line thickness.
Employing resistive touch-panel technology, the STM32TS60 controller offers customers a real alternative and complements the recent industry trend for using capacitive touch technology. Resistive technology is a cost effective and mature high-volume solution that has seen dramatically improved performance over the past few years in terms of durability and display transparency. In addition, it easily overcomes EMI (electromagnetic interference) noise issues, which can be an inherent limitation with alternative touch technologies. Resistive technology is already widely used in PDAs and similar touch-enabled devices and the screens are readily available in standard LCD sizes and at competitive prices.
The new chip combines the company’s highly efficient STM32 microcontroller architecture with PMatrixTM Multi-Touch technology from ST‘s partner Stantum, a leader in touch-sensing processing, to achieve fast response times while minimizing system complexity and component count.
The STM32TS60 single-core microcontroller is an added-value solution compared to other expensive multi-core processor or digital signal processors (DSPs) requiring specialized programming expertise.
“The STM32T60 is the first member of ST’s new STMTouch family and provides a very low power, highly reliable alternative to capacitive touchscreen solutions,” said Jim Nicholas, General Manager of ST’s Microcontrollers Division. “By leveraging the advanced processing and low power of the STM32 and STM8 processor platforms, and supporting different touchscreen capabilities, STMTouch is a versatile platform for next-generation consumer devices offering compelling features, increased flexibility and more fun for users.”
The STM32TS60’s high EMI immunity makes it suitable for use in multi-function wireless products such as cellphones, notebook PCs, netbooks and mobile Internet devices. Moreover, its low power consumption helps to maximize operating times and recharge intervals, and is a direct benefit of the STM32’s energy-saving design features and ARM® Cortex™-M3 processor conceived for power-sensitive embedded applications. In addition, very-low-power idle mode with ‘wake-up on touch only’ helps further extend mobile battery life.
The STM32TS60 is housed in a 7 x 7mm 144-pin UFBGA package, and is now sampling to lead customers. Volume production is expected for Q2 2010.
About STMicroelectronics
STMicroelectronics is a global leader serving customers across the spectrum of electronics applications with innovative semiconductor solutions. ST aims to be the undisputed leader in multimedia convergence and power applications leveraging its vast array of technologies, design expertise and combination of intellectual property portfolio, strategic partnerships and manufacturing strength. In 2008, the Company's net revenues were $9.84 billion. Further information on ST can be found at www.st.com.
Last News
2010-06-15
TxCell achève avec succès le développement préclinique de TX-RAD pour traiter les arthrites inflammatoires. Ces résultats favorables permettront à TxCell de démarrer prochainement un nouvel essai clinique de Phase I/IIa
2010-06-08
Zealand Pharma Announces An Extension of The Lixisenatide Global Licensing Agreement with sanofi-aventis for Type-2 Diabetes
2010-06-02
Cytheris Closes €12 Million ($15 Million) Series D Financing
2010-05-20
Novaled demonstrates long lifetime and high efficiency white top emitting OLEDs
2010-04-29
Novaled demonstrates reliable OLEDs on metal substrates
2010-04-26
ASK and FORMASET to create a Joint Venture in Brazil Newly founded ASK-FORMASET will address the South American market
2010-04-26
Maeglin Software annonce la signature de trois partenariats de distribution avec Sagem-Orga, ZTE, et SAB Communication
2010-04-20
Maeglin Software annonce la signature de deux nouveaux clients
2010-04-15
Positive Phase III Diabetes Data with Lixisenatide Announced by Zealand Pharma’s Partner sanofi-aventis
2010-04-10
Cooperation between Novaled and Ingo Maurer on transparent OLED Lamps
2010-04-07
Gerd Günther joins Novaled Management Board
2010-04-01
Marseilles Provence Metropolis offers full contactless ticketing with ASK
2010-03-16
Cytheris Announces Publication of Preclinical Study in Journal of Immunology Showing Interleukin-7 Promotes T Cell Viability, Trafficking, and Functionality While Improving Survival in Sepsis
2010-03-16
6WIND Provides 10x Acceleration of Packet Processing Functions on New Multi-Core Intel® Platforms
2010-03-16
6WIND Provides 10x Acceleration of Packet Processing Functions on New Multi-Core Intel® Platforms
2010-03-15
KUROS MEETS PRIMARY EFFICACY ENDPOINT IN PHASE IIB STUDY WITH KUR-111 RESULTS PROVIDE FIRST CLINICAL PROOF OF PRINCIPLE FOR KUROS’ BIOACTIVE-BIOMATERIAL PRODUCT PLATFORM
2010-03-11
German Novaled AG receives Clean Equity Award 2010
2010-03-07
Expanded Technology Partnership to Increase Integration of 6WIND’s Multicore Embedded Networking Software with Emerson Network Power’s AdvancedTCA® Platforms
2010-02-24
Transgenomic Licenses IP From IntegraGen to Develop Genetic Test for Autism
2010-02-03
Entrepreneurs et Investisseurs Technologies annonce l’acquisition de la société Adeon
2010-01-25
Fluidigm, IntegraGen form French Alliance
2010-01-06
STMicroelectronics Pushes the Multi-Touch Screen Market and Unveils Resistive Multi-Touch Single-Chip Controller with Unrivaled Performance
